Dtsch Med Wochenschr 2014; 139(40): 2020-2022
DOI: 10.1055/s-0034-1370288
Verdauungs- und Stoffwechselkrankheiten | Commentary
Gastroenterologie, Hepatologie
© Georg Thieme Verlag KG Stuttgart · New York

Autoimmune Hepatitis – aktuelle Entwicklungen einer zunehmenden Erkrankung

Autoimmune hepatitis: news about a disease on the rise
R. Zenouzi
1   I. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Infektiologie, Universitätsklinikum Hamburg-Eppendorf
,
J. Hartl
1   I. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Infektiologie, Universitätsklinikum Hamburg-Eppendorf
,
A. W. Lohse
1   I. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Infektiologie, Universitätsklinikum Hamburg-Eppendorf
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
17. Oktober 2014 (online)

    Lizenzen und Reprints

Schlüsselwörter

autoimmune Hepatitis - Diagnose-Score - Immunsuppression - Lebensqualität

Keywords

autoimmune hepatitis - diagnostic score - immunosuppression - quality of life
 

  • Literatur

  • 1 Baven-Pronk AM, Coenraad MJ, van Buuren HR et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Alimentary Pharmacol Ther 2011; 34: 335-343
    CrossrefGoogle Scholar
  • 2 Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology 2011; 140: 1472-1480
    CrossrefGoogle Scholar
  • 3 de Boer YS, van Gerven NM, de Boer NK et al. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Alimentary Pharmacol Ther 2013; 37: 640-646
    CrossrefGoogle Scholar
  • 4 Dhaliwal HK, Anderson R, Thornhill EL et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56: 1401-1408
    CrossrefGoogle Scholar
  • 5 Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612-617
    CrossrefGoogle Scholar
  • 6 Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
    CrossrefGoogle Scholar
  • 7 Hoeroldt B, McFarlane E, Dube A et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-1989
    CrossrefGoogle Scholar
  • 8 Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011; 55: 171-182
    CrossrefGoogle Scholar
  • 9 Manns MP, Czaja AJ, Gorham JD et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213
    CrossrefGoogle Scholar
  • 10 Manns MP, Woynarowski M, Kreisel W et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
    CrossrefGoogle Scholar
  • 11 Ngu JH, Gearry RB, Frampton CM et al. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 2013; 57: 2399-2406
    CrossrefGoogle Scholar
  • 12 Qiu D, Wang Q, Wang H et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011; 54: 340-347
    CrossrefGoogle Scholar
  • 13 Schramm C, Wahl I, Weiler-Normann C et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol 2014; 60: 618-624
    CrossrefGoogle Scholar
  • 14 van Gerven NM, Verwer BJ, Witte BI et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-147
    CrossrefGoogle Scholar
  • 15 Weiler-Normann C, Schramm C, Quaas A et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58: 529-534
    CrossrefGoogle Scholar